Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

July 31, 2011

Conditions
Breast CancerNeoplasm Metastasis
Interventions
DRUG

Non pegylated liposomal doxorubicin and docetaxel

max. 6 courses

Trial Locations (10)

5211 NL

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch

9400 RA

Wilhelmina Ziekenhuis, Assen

5602 ZA

Catharina-Ziekenhuis, Eindhoven

4380 DD

Ziekenhuis Walcheren, Flushing

3083 AN

Ikazia Ziekenhuis, Rotterdam

5000 LC

Sint Elisabeth Ziekenhuis, Tilburg

3527 CE

Mesos Medisch Centrum, Utrecht

5500 MB

Maxima Medisch Centrum, Veldhoven

5900 BX

VieCuri MC, Venlo

7100 GG

Streekziekenhuis Koningin Beatrix, Winterswijk

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Cephalon

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

Catharina Ziekenhuis Eindhoven

OTHER

NCT00377559 - Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter